Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 No robust evidence of lumefantrine resistance.

Literature DB >> 26276895

No robust evidence of lumefantrine resistance.

Kamal Hamed¹, Kelli Kuhen².

Abstract

Entities: Chemical

Mesh：

Substances：

Year: 2015 PMID： 26276895 PMCID： PMC4538496 DOI： 10.1128/AAC.00329-15

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

× No keyword cloud information.

7 in total

1. Efficacy of artemether-lumefantrine and dihydroartemisinin-piperaquine for treatment of uncomplicated malaria in children in Zaire and Uíge Provinces, angola.

Authors: Mateusz M Plucinski; Eldin Talundzic; Lindsay Morton; Pedro Rafael Dimbu; Aleixo Panzo Macaia; Filomeno Fortes; Ira Goldman; Naomi Lucchi; Gail Stennies; John R MacArthur; Venkatachalam Udhayakumar
Journal: Antimicrob Agents Chemother Date: 2014-11-03 Impact factor: 5.191

Review 2. Update on the in vivo tolerance and in vitro reduced susceptibility to the antimalarial lumefantrine.

Authors: Alexis Nzila; John Okombo; Eric Ohuma; Assad Al-Thukair
Journal: J Antimicrob Chemother Date: 2012-07-02 Impact factor: 5.790

3. Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria.

Authors: F Ezzet; M van Vugt; F Nosten; S Looareesuwan; N J White
Journal: Antimicrob Agents Chemother Date: 2000-03 Impact factor: 5.191

Review 4. Clinical pharmacokinetics and pharmacodynamics and pharmacodynamics of artemether-lumefantrine.

Authors: N J White; M van Vugt; F Ezzet
Journal: Clin Pharmacokinet Date: 1999-08 Impact factor: 6.447

5. Molecular and pharmacological determinants of the therapeutic response to artemether-lumefantrine in multidrug-resistant Plasmodium falciparum malaria.

Authors: Ric N Price; Anne-Catrin Uhlemann; Michele van Vugt; Al Brockman; Robert Hutagalung; Shalini Nair; Denae Nash; Pratap Singhasivanon; Tim J C Anderson; Sanjeev Krishna; Nicholas J White; François Nosten
Journal: Clin Infect Dis Date: 2006-04-26 Impact factor: 9.079

6. Adherence and efficacy of supervised versus non-supervised treatment with artemether/lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Bangladesh: a randomised controlled trial.

Authors: Md Mushfiqur Rahman; Arjen M Dondorp; Nicholas P J Day; Niklas Lindegardh; Mallika Imwong; M A Faiz; A Mannan Bangali; A T M Mustafa Kamal; Jahirul Karim; Jaranit Kaewkungwal; Pratap Singhasivanon
Journal: Trans R Soc Trop Med Hyg Date: 2008-07-07 Impact factor: 2.184

Review 7. The content of African diets is adequate to achieve optimal efficacy with fixed-dose artemether-lumefantrine: a review of the evidence.

Authors: Zulfiqarali G Premji; Salim Abdulla; Bernhards Ogutu; Alice Ndong; Catherine O Falade; Issaka Sagara; Nathan Mulure; Obiyo Nwaiwu; Gilbert Kokwaro
Journal: Malar J Date: 2008-11-25 Impact factor: 2.979

7 in total

5 in total

No robust evidence of lumefantrine resistance.

1. Efficacy of artemether-lumefantrine and dihydroartemisinin-piperaquine for treatment of uncomplicated malaria in children in Zaire and Uíge Provinces, angola.

Review 2. Update on the in vivo tolerance and in vitro reduced susceptibility to the antimalarial lumefantrine.

3. Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria.

Review 4. Clinical pharmacokinetics and pharmacodynamics and pharmacodynamics of artemether-lumefantrine.

5. Molecular and pharmacological determinants of the therapeutic response to artemether-lumefantrine in multidrug-resistant Plasmodium falciparum malaria.

6. Adherence and efficacy of supervised versus non-supervised treatment with artemether/lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Bangladesh: a randomised controlled trial.

Review 7. The content of African diets is adequate to achieve optimal efficacy with fixed-dose artemether-lumefantrine: a review of the evidence.

1. Reply to "no robust evidence of lumefantrine resistance".

Review 2. Plasmodium falciparum drug resistance in Angola.

Review 3. New developments in anti-malarial target candidate and product profiles.

Review 4. Resistance to Artemisinin Combination Therapies (ACTs): Do Not Forget the Partner Drug!

Review 5. The genomic architecture of antimalarial drug resistance.